The pharma group did not break down the details of the license to get control of STX-478, described as a next-generation PI3K alpha inhibitor for breast cancer and other advanced solid tumours ...

Shares of Eli Lilly were down 1.7% in midday trade. As part of the deal, Eli Lilly will acquire Scorpion's STX-478, an investigative once-daily oral medication being evaluated in a trial.

Eli Lilly has agreed to acquire Scorpion Therapeutics’ breast cancer treatment program for up to $2.5 billion in cash. The drugmaker said Monday it is acquiring Scorpion and its STX-478 program ...

On the call, Recursion highlighted REC-7735 preclinical data, suggesting differentiation from Scorpion Therapeutics’ STX-478, which was acquired by Eli Lilly (LLY) earlier this year. To moderate ...